Weekly Digest - 25-31 Mar 2023
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - 25-31 Mar 2023
30 Mar 2023: Opdivo (Nivolumab) (IV) / Neoadjuvant NSCLC / BMS: Long-term clinical benefits were observed in 3 years follow up in CheckMate -816 study
- The CheckMate -816 trial demonstrates long-term, durable clinical benefits for patients with respectable non-small cell lung cancer after three years
- Updated data showed Opdivo and Chemotherapy improve event-free survival and time to distant metastasis, as well as an encouraging trend towards overall survival when compared to Chemotherapy alone
- Updated results from CheckMate -816 trial evaluating Opdivo + Chemo vs Chemo in Neoadjuvant setting:
- EFS: Opdivo + Chemo (57%) vs Chemo (43%)
- OS: Immature (will continue to be followed for upcoming analyses)
- Safety profile was consistent with the primary analysis, with no new safety signals
- CheckMate -816 is the first positive Phase 3 trial with an immunotherapy-based combination in the neoadjuvant setting of NSCLC
- Updated results will be presented in ELCC 2023
